ICD-10 Z72.0 is officially defined as "Tobacco use." code Z72.0 is referenced in 8 tracked payer policy changes from Blue Cross Blue Shield of Rhode Island and Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code Z72.0 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
BCBSRI has implemented multiple policy changes affecting preventive services, coding, and reimbursement across various specialties. Key changes include new breast cancer screening coverage requirements, updated STI testing billing procedures, hearing aid coverage increases, and several new CPT/HCPCS codes for various services.
Aetna considers measurement of plasma brain natriuretic peptide (BNP) medically necessary to differentiate dyspnea due to heart failure from pulmonary disease, to determine prognosis or severity in chronic heart failure, to screen for heart failure annually in adults with diabetes mellitus, to measure upon hospital admission and before discharge in acutely decompensated heart failure, for preoperative cardiac risk assessment before elevated-risk noncardiac surgery in members with known cardiovascular disease, age 65 or older, or age 45 or older with cardiovascular symptoms, and as an adjunct test for risk stratification of Stage C aortic stenosis. Serial BNP and NT-proBNP measurements and the other uses listed in the policy, such as diagnosing Kawasaki disease, are considered experimental, investigational, or unproven. CPT 83880 is covered when the selection criteria are met, except as a cardiovascular biomarker in healthy normal subjects and for identifying stress-induced myocardial ischemia.
Aetna considers spinal fusion with instrumentation and bone grafting medically necessary for idiopathic scoliosis with a curve of 40 degrees or greater in an adolescent younger than 18, or a curve of 50 degrees or greater in a young adult aged 18 to 25. Lumbar vertebral body tethering is considered medically necessary for skeletally immature members with lumbar idiopathic scoliosis whose lumbar curve is between 40 and 65 degrees, whose curve reduces by 50 percent or more on side-bending radiographs, and who have no sagittal imbalance, while vertebral body tethering for thoracic scoliosis is listed as experimental, investigational or unproven. Braces are considered medically necessary when the Boston, Charleston, Milwaukee, Providence, Rigo-Cheneau, standard TLSO and other listed types are prescribed by a qualified practitioner and furnished by a licensed or certified orthotist or prosthetist within six months of the prescription, while the Copes, SpineCor, Rosenberger, ScoliBrace, UNYQ and Whisper braces are considered experimental, investigational or unproven.
Aetna covers annual low-dose CT (LDCT) lung cancer screening, CPT 71271, for current or former smokers ages 50 to 80 with a 20 pack-year or more smoking history, and former smokers must have quit within the past 15 years. Annual LDCT is also covered for surveillance of non-small cell lung cancer, starting 2 years after definitive treatment, using CPT 71250. Artificial intelligence-based imaging, computer-aided detection for chest radiographs, PET for lung cancer screening, and LDCT screening for other indications such as asbestos-exposed individuals are considered experimental, investigational or unproven.
Aetna's Clinical Policy Bulletin 0743 sets medical necessity criteria for cervical, thoracic and lumbar laminectomy, laminoplasty, spinal fusion, vertebral corpectomy, and removal of spinal instrumentation. Most covered indications require advanced imaging (CT or MRI) showing at least moderate central, lateral recess or foraminal stenosis, or nerve root or spinal cord compression, at the level matching the clinical findings, and failure of at least 6 weeks of conservative therapy, or 3 months for certain fusion indications such as scoliosis, kyphosis and sub-axial instability. Computer-assisted surgical navigation is approvable only when fusion implants are placed during surgery, and it is not approvable during routine decompression surgery.
Aetna's Clinical Policy Bulletin 0244 sets the coverage rules for skin and soft tissue substitutes used on chronic wounds. Aetna considers these products medically necessary for chronic wounds that failed to respond to treatment when the member is 18 or older, is a non-smoker or has completed or is enrolled in smoking cessation therapy, and the wound is a partial- or full-thickness skin defect of at least 1 cm2 that has not improved after at least four weeks of standard wound care. Diabetic foot ulcers, venous leg ulcers and partial- or full-thickness burn wounds have additional criteria, each listed product has its own indications, and pressure ulcer treatment and other uses are considered not medically necessary, experimental, investigational or unproven.
Aetna considers spinal fusion with instrumentation and bone grafting medically necessary for idiopathic scoliosis with a curve of 40 degrees or greater in an adolescent younger than 18, or a curve of 50 degrees or greater in a young adult aged 18 to 25. Lumbar vertebral body tethering is considered medically necessary for skeletally immature members with a lumbar idiopathic scoliosis curve between 40 and 65 degrees that is flexible with at least 50% reduction on side-bending radiographs and no sagittal imbalance, and the MAGEC System and Shilla growth guidance technique are considered medically necessary growing rods for members who meet the surgery criteria. The policy lists the Boston, Charleston, Milwaukee, Peak Scoliosis Bracing System, Providence, Rigo-Cheneau, Risser jacket, standard TLSO and TechnoSpine TLSO-Scoliosis Brace as medically necessary durable medical equipment, and it considers the Copes, SpineCor, ScoliBrace, UNYQ, Whisper and Rosenberger braces, the Schroth method, vertebral body stapling, ApiFix, genetic testing such as ScoliScore, and other listed methods experimental, investigational or unproven.
Aetna considers measurement of plasma BNP medically necessary to differentiate dyspnea due to heart failure from pulmonary disease, to determine prognosis or disease severity in chronic heart failure, to screen adults with diabetes annually for heart failure, to measure on hospital admission for prognosis in acutely decompensated heart failure, to measure before hospital discharge to inform postdischarge prognosis, to assess preoperative cardiac risk for elevated-risk noncardiac surgery in members with known cardiovascular disease, age 65 or older, or age 45 or older with CVD symptoms, and as an adjunct test for risk stratification of individuals with severe (Stage C) aortic stenosis. Serial measurements of plasma BNP or NT-proBNP are considered experimental, investigational or unproven for all other indications, including monitoring or titrating therapy in chronic heart failure, routine evaluation of dyspnea other than to distinguish heart failure from pulmonary disease, and screening for unrecognized left ventricular dysfunction. CPT 83880 is covered when selection criteria are met, except as a cardiovascular biomarker in healthy normal subjects and for identifying stress-induced myocardial ischemia.
Watch Z72.0
Get one email when a payer policy names Z72.0, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.
Get alerts for changes like this
Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.